- Home
- AMGN vs SAN Comparison
AMGN vs SAN Comparison
Compare AMGN & SAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMGN
- SAN
- Stock Information
- Founded
- AMGN 1980
- SAN 1857
- Country
- AMGN United States
- SAN Spain
- Employees
- AMGN N/A
- SAN N/A
- Industry
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- SAN Commercial Banks
- Sector
- AMGN Health Care
- SAN Finance
- Exchange
- AMGN Nasdaq
- SAN Nasdaq
- Market Cap
- AMGN 150.8B
- SAN 125.3B
- IPO Year
- AMGN N/A
- SAN 1987
- Fundamental
- Price
- AMGN $275.14
- SAN $10.00
- Analyst Decision
- AMGN Hold
- SAN Strong Buy
- Analyst Count
- AMGN 19
- SAN 1
- Target Price
- AMGN $320.11
- SAN N/A
- AVG Volume (30 Days)
- AMGN 1.9M
- SAN 4.2M
- Earning Date
- AMGN 10-29-2025
- SAN 10-28-2025
- Dividend Yield
- AMGN 3.47%
- SAN 1.67%
- EPS Growth
- AMGN 110.88
- SAN 17.29
- EPS
- AMGN 12.23
- SAN 0.97
- Revenue
- AMGN $34,917,000,000.00
- SAN $58,905,460,953.00
- Revenue This Year
- AMGN $8.94
- SAN $22.88
- Revenue Next Year
- AMGN $1.71
- SAN N/A
- P/E Ratio
- AMGN $22.45
- SAN $10.33
- Revenue Growth
- AMGN 12.88
- SAN 5.45
- 52 Week Low
- AMGN $253.30
- SAN $4.43
- 52 Week High
- AMGN $339.17
- SAN $10.16
- Technical
- Relative Strength Index (RSI)
- AMGN 37.65
- SAN 62.44
- Support Level
- AMGN $271.61
- SAN $9.96
- Resistance Level
- AMGN $277.80
- SAN $10.12
- Average True Range (ATR)
- AMGN 4.94
- SAN 0.12
- MACD
- AMGN -0.71
- SAN 0.01
- Stochastic Oscillator
- AMGN 20.61
- SAN 81.01
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
About SAN Banco Santander S.A. Sponsored ADR (Spain)
Santander's focus is on retail and commercial banking. Latin America is geographically the most significant operation, with Brazil making the largest contribution. Its continental European business is mainly in Spain and Portugal. Santander's UK presence is the result of its acquisition of Abbey building society. In the US, Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.